|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.3647 - 0.3940|
|52 Week Range||0.2660 - 0.6170|
|Beta (5Y Monthly)||2.02|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
ATB Capital said in its latest report that Khiron’s strategy of vertical integration supports sales growth at attractive margins and as medical cannabis revenue increases, they expect Khiron’s sales growth and gross margin expansion to be meaningful over the long term, supporting a constructive outlook.
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country ...